# Evaluation of the salivary biomarker cortisol in patients with temporomandibular disorders

**Authors:** Bruno Macedo de Sousa, Nansi Lopez-Valverde, Carla Cardoso, Antonio Lopez-Valverde, Maria J. Rodrigues, Jose A. Blanco Rueda

PMC · DOI: 10.22514/jofph.2026.007 · 2026-01-12

## TL;DR

This study found that patients with temporomandibular disorders have higher cortisol levels in their saliva, suggesting a link between stress and the condition.

## Contribution

The study provides new evidence linking TMD with elevated salivary cortisol, indicating HPA axis dysregulation.

## Key findings

- TMD patients had significantly higher salivary cortisol levels than healthy controls.
- No significant correlation was found between age and cortisol levels in participants.

## Abstract

Background: Temporomandibular Disorders (TMD) are musculoskeletal and 
neuromuscular conditions involving the temporomandibular joint (TMJ), masticatory 
muscles, and related structures. Stress can trigger dysregulation of the 
hypothalamic-pituitary-adrenal (HPA) axis, leading to increased cortisol 
secretion. Salivary cortisol assessment provides a non-invasive method to 
investigate this relationship. Methods: A total of 98 participants were 
recruited—49 patients diagnosed with TMD and 49 healthy controls—at the 
Faculty of Medicine of the University of Coimbra. Participants were evaluated 
according to the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD). 
Saliva samples were collected between 9:00 and 11:00 AM, processed with 
Enzyme-Linked Immunosorbent Assay (ELISA), and analyzed statistically using 
Shapiro-Wilk and Mann-Whitney tests, with a 95% confidence level. 
Results: Salivary cortisol levels were significantly higher in TMD 
patients (mean = 17.55 nmol/L) compared with controls (mean = 11.09 nmol/L; 
p = 0.0032). No significant correlations were found between age and 
cortisol levels. Conclusions: Patients with TMD present higher salivary 
cortisol levels, suggesting dysregulation of the HPA axis associated with stress. 
These findings support the integration of psychosocial factors into the 
management of TMD. Clinical Trial Registration: 
ClinicalTrials.gov identifier NCT06874868.

## Linked entities

- **Diseases:** TMD (MONDO:0005473)

## Full-text entities

- **Genes:** IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}
- **Diseases:** DC (MESH:D054221), HPA axis hyperactivity (MESH:D007029), HPA axis dysfunction (MESH:D007027), chronic pain (MESH:D059350), muscle disorders (MESH:D009135), depression (MESH:D003866), joint disorders (MESH:D007592), Orofacial Pain (MESH:D005157), pain (MESH:D010146), disc displacement (MESH:D007405), TMD (MESH:D013705), anxiety (MESH:D001007), inflammation (MESH:D007249)
- **Chemicals:** glutamate (MESH:D018698), Cortisol (MESH:D006854), EQ 6141-9601 S (-), caffeine (MESH:D002110), carbohydrate (MESH:D002241)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12853154/full.md

---
Source: https://tomesphere.com/paper/PMC12853154